
SK Biopharmaceuticals licences epilepsy drug from Biohaven
Biohaven and SK Biopharmaceuticals have agreed a strategic global licensing and collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven’s Kv7 ion channel platform. The platform is led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase II/III development… Read More




